TMX group

AURORA, ON, June 26 /CNW/ - Helix BioPharma Corp. (TSX: HBP), a developer
of novel cancer therapeutics, today announced that Dr. Heman Chao, VP
Research, will be presenting a poster at the 5th Annual Congress on
Recombinant Antibodies Conference, in Zurich Switzerland. The poster entitled
"L-DOS47 - a novel lung adenocarcinoma specific immuno-conjugate therapeutic",
highlights the ability of L-DOS47 to target and kill lung tumour cells in
vitro and in tumour bearing mice, as well as L-DOS47's ability to enhance the
effect of weakly basic chemotherapeutics. L-DOS47 is the first          
immuno-conjugate therapeutic candidate derived from Helix's novel anti-cancer
DOS47 platform technology.
The poster further highlights L-DOS47's ability to bind specifically to
human lung adenocarcinoma as shown by tissue specific staining. Imaging
studies using A549 xenografts and intravenously administered labelled L-DOS47
showed that the drug molecule preferentially accumulated at the tumour site
and persisted at the site for more than 72 hours, consistent with strong
antibody binding. In addition, in vitro experiments showed that L-DOS47
potentiated the cytotoxic effect of a number of chemotherapeutics. In some
instances, less than one tenth of the normal drug dose was required to achieve
the desired inhibition of cell growth.
"These early findings provide further evidence of the specific nature of
the targeting antibody in our immuno-conjugate, as well as provides evidence
that L-DOS47 may have the ability to enhance the action of currently marketed
chemotherapeutic products," said Dr. Don Segal, President and CEO of Helix
BioPharma Corp. "They are encouraging and suggest that L-DOS47 may have
potential as a lung cancer therapy."
A copy of the presentation will be available on Helix's website for
download (http://www.helixbiopharma.com).
During the same conference, Helix's collaboration partner, the Institute
for Biological Sciences of the National Research Council of Canada (NRC-IBS)
will be presenting research work on the antibody that is used in L-DOS47. Dr.
Jianbing Zhang of NRC-IBS has been selected by the organizing committee to
give an oral presentation entitled "ES1, A pentabody with novel specificity to
non-small cell lung carcinoma."
The 5th Annual Congress on Recombinant Antibodies Conference is organized
by Informa Life Sciences and runs from June 27 to June 30th at the Renaissance
Zurich Hotel in Zurich Switzerland. The conference is a premier meeting place
for scientists and executives from the biotechnology and pharmaceutical
industries, as well as academics, to showcase the latest research innovations
related to antibodies and immuno-conjugates for human therapies.

About the National Research Council Institute for Biological Sciences
(NRC-IBS)

Recognized globally for research and innovation, the NRC is a leader in
the development of an innovative, knowledge-based economy for Canada through
science and technology. The NRC operates world-class research facilities, as
well as information, technology and innovation support networks from coast to
coast. Its outstanding people help turn ideas and knowledge into new products,
processes and services, creating value for Canada. The NRC works hand in hand
with partners from industry, government and universities to help ignite the
spark of innovation in communities across the land and to give Canadian
companies a competitive edge in today's marketplace (www.nrc-cnrc.gc.ca). With
over 75 years of research excellence, the NRC Institute for Biological
Sciences (NRC-IBS) consists of a team of leading life science researchers
dedicated to spearheading the next breakthrough discoveries and technologies
in neurobiology, immunobiology and glycobiology. Driven by these challenges,
NRC-IBS is focused on innovative research of interest to the healthcare and
pharmaceutical sectors.

About Helix BioPharma

Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its Topical
Interferon Alpha-2b, for the treatment of conditions caused by the human
papilloma virus, and its novel L-DOS47 new drug candidate. Helix is listed on
the TSX under the symbol "HBP".

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not
accept responsibility for the adequacy or accuracy of the content of this News
Release. The presentations referred to in this News Release are subject to
change or cancellation without notice. Helix BioPharma Corp. ("Helix" or the
"Company") has relied solely on NRC-IBS for the information about NRC-IBS
provided in this News Release and the Company disclaims any liability with
respect to such information. Helix disclaims responsibility for information
contained in any linked or referenced website, and such links and references
do not constitute an endorsement by Helix of those or any other website. This
News Release contains certain forward-looking statements regarding the
Company's research and development initiatives and in particular, L-DOS47,
which statements can be identified by the use of forward-looking terminology
such as "may", "encouraging", "potential", "suggest", "will", or comparable
terminology referring to future events or results. Forward looking statements
are statements about the future and are inherently uncertain, and Helix's
actual results could differ materially from those anticipated in these  
forward-looking statements as a result of numerous factors, including without
limitation, uncertainty whether DOS47 or L-DOS47 will be successfully
developed as a drug or otherwise commercialized; the need for additional
research and development, the outcome of which is uncertain; the need for
clinical trials, the occurrence and success of which cannot be assured;
product liability and insurance risks; the risk of technical obsolescence; the
need for regulatory approvals, which may not be obtained in a timely matter or
at all; intellectual property risks; marketing/manufacturing and
partnership/strategic alliance risks; the effect of competition; Helix's need
for additional future capital, which may not be available in a timely manner
or at all; as well as a description of other risks and uncertainties affecting
Helix and its business, as contained in news releases and filings with the
Canadian Securities Regulatory Authorities, any of which could cause actual
results to vary materially from current results or Helix's anticipated future
results. Forward-looking statements are based on the beliefs, opinions and
expectations of Helix's management at the time they are made, and Helix does
not assume any obligation to update any forward-looking statement should those
beliefs, opinions or expectations, or other circumstances change.